- Home
- OCFC vs AUPH Comparison
OCFC vs AUPH Comparison
Compare OCFC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- AUPH
- Stock Information
- Founded
- OCFC 1902
- AUPH 1993
- Country
- OCFC United States
- AUPH Canada
- Employees
- OCFC N/A
- AUPH N/A
- Industry
- OCFC Major Banks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- AUPH Health Care
- Exchange
- OCFC Nasdaq
- AUPH Nasdaq
- Market Cap
- OCFC 983.2M
- AUPH 1.1B
- IPO Year
- OCFC 1996
- AUPH 1999
- Fundamental
- Price
- OCFC $18.78
- AUPH $7.58
- Analyst Decision
- OCFC Buy
- AUPH Strong Buy
- Analyst Count
- OCFC 4
- AUPH 2
- Target Price
- OCFC $21.25
- AUPH $11.50
- AVG Volume (30 Days)
- OCFC 288.7K
- AUPH 1.6M
- Earning Date
- OCFC 07-17-2025
- AUPH 07-31-2025
- Dividend Yield
- OCFC 4.26%
- AUPH N/A
- EPS Growth
- OCFC N/A
- AUPH N/A
- EPS
- OCFC 1.53
- AUPH 0.27
- Revenue
- OCFC $369,879,000.00
- AUPH $247,295,000.00
- Revenue This Year
- OCFC N/A
- AUPH $12.15
- Revenue Next Year
- OCFC $12.29
- AUPH $18.31
- P/E Ratio
- OCFC $12.28
- AUPH $28.53
- Revenue Growth
- OCFC N/A
- AUPH 29.20
- 52 Week Low
- OCFC $14.29
- AUPH $5.20
- 52 Week High
- OCFC $21.87
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- OCFC 72.18
- AUPH 40.36
- Support Level
- OCFC $17.47
- AUPH $7.29
- Resistance Level
- OCFC $17.62
- AUPH $8.86
- Average True Range (ATR)
- OCFC 0.41
- AUPH 0.34
- MACD
- OCFC 0.17
- AUPH -0.06
- Stochastic Oscillator
- OCFC 95.71
- AUPH 19.37
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.